Novel Therapies for Thyroid Autoimmune Diseases: an update

A Th1 immune-preponderance has been shown in the immunopathogenesis of autoimmune thyroiditis (AT), Graves' disease (GD) and Graves' Ophthalmopathy (GO), in which the Th1-chemokines (CXCL9, CXCL10, CXCL11), and their (C-X-C)R3 receptor, have a crucial role. Methimazole, and corticosteroids have been shown to modulate these chemokines; several efforts have been done to modulate the autoimmune reaction with other drugs, i.e. PPAR-gamma, or -alpha ligands, or antibodies, or small molecules directed against CXCL10, or CXCR3.Antigen-specific therapy for GD, by inducing T cell tolerance through an immunization with TSH-R peptides, has been published.Drugs targeting cytokines [anti-TNF alpha (Etanercept), and anti-IL-6 (Tocilizumab)], and RTX (a chimeric monoclonal antibody vs. CD20) have been used in GO, with promising results. Teprotumumab (a human monoclonal anti-IGF-1R blocking antibody) has been investigated in a trial, showing it was very effective in GO patients. Still, more studies are needed for new therapies targeting autoimmune thyroid disorders. (C) 2019 Elsevier Ltd. All rights reserved.